Market revenue in 2023 | USD 24.8 million |
Market revenue in 2030 | USD 80.3 million |
Growth rate | 18.3% (CAGR from 2023 to 2030) |
Largest segment | Cytokines & growth factors |
Fastest growing segment | Cytokines & Growth Factors |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cytokines & Growth Factors, Antibodies, Immune checkpoint proteins, Virus Antigens, Enzymes, Recombinant Regulatory Protein, Hormones |
Key market players worldwide | Thermo Fisher Scientific Inc, Danaher Corp, Bio-Techne Corp, Sino Biological, Miltenyi Biotec, Proteintech Group, Prospec, New England Biolabs |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to research-grade proteins market will help companies and investors design strategic landscapes.
Cytokines & growth factors was the largest segment with a revenue share of 22.58% in 2023. Horizon Databook has segmented the South Korea research-grade proteins market based on cytokines & growth factors, antibodies, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory protein, hormones covering the revenue growth of each sub-segment from 2018 to 2030.
Research-grade proteins are in demand by professionals operating in the pharmaceutical & biotechnology industry in the country. For instance, in September 2023, Samsung’s Life Science invested in AimedBio, a Korea-based biotechnology company focused on Antibody-drug Conjugates (ADC).
The ADC technology aims to improve anticancer therapeutic effects with minimum damage to nontumor cells. In May 2023, PharmAbcine obtained authorization from the Korean Ministry of Food and Drug Safety (MFDS) for the Investigational New Drug (IND) application purpose.
This clearance has led to the commencement of Phase I clinical trial for PMC-403, intended for the treatment of Neovascular Age-related Macular Degeneration (nAMD).
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea research-grade proteins market , including forecasts for subscribers. This country databook contains high-level insights into South Korea research-grade proteins market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account